These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 3543527)
1. Immunotoxin therapy of malignant melanoma. Spitler LE Med Oncol Tumor Pharmacother; 1986; 3(3-4):147-52. PubMed ID: 3543527 [TBL] [Abstract][Full Text] [Related]
2. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Zovickian J; Johnson VG; Youle RJ J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171 [TBL] [Abstract][Full Text] [Related]
3. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Spitler LE; del Rio M; Khentigan A; Wedel NI; Brophy NA; Miller LL; Harkonen WS; Rosendorf LL; Lee HM; Mischak RP Cancer Res; 1987 Mar; 47(6):1717-23. PubMed ID: 3493066 [TBL] [Abstract][Full Text] [Related]
4. Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin. Spitler LE; Mischak R; Scannon P Int J Rad Appl Instrum B; 1989; 16(6):625-7. PubMed ID: 2606718 [No Abstract] [Full Text] [Related]
5. Monoclonal antibody immunoconjugates in the diagnosis and treatment of advanced melanoma. Bhardwaj S Mt Sinai J Med; 1992 May; 59(3):207-10. PubMed ID: 1603109 [TBL] [Abstract][Full Text] [Related]
7. Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors. O'Connell MJ; Chen ZJ; Yang H; Yamada M; Massaro M; Mittelman A; Ferrone S Semin Surg Oncol; 1989; 5(6):441-7. PubMed ID: 2688034 [TBL] [Abstract][Full Text] [Related]
8. Prospects for immunotoxin therapy of non-Hodgkin's lymphoma. Grossbard ML; Fidias P Clin Immunol Immunopathol; 1995 Aug; 76(2):107-14. PubMed ID: 7614729 [TBL] [Abstract][Full Text] [Related]
13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
14. [Use of antibodies or their fragments for the treatment of tumors]. Douillard JY; Chatal JF Bull Cancer; 1998 Nov; 85(11):951-9. PubMed ID: 9951422 [TBL] [Abstract][Full Text] [Related]
15. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092 [TBL] [Abstract][Full Text] [Related]
16. The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma. Engert A; Sausville EA; Vitetta E Curr Top Microbiol Immunol; 1998; 234():13-33. PubMed ID: 9670610 [TBL] [Abstract][Full Text] [Related]
17. Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL. Mischak RP; Foxall C; Rosendorf LL; Knebel K; Scannon PJ; Spitler LE Mol Biother; 1990 Jun; 2(2):104-9. PubMed ID: 2363853 [TBL] [Abstract][Full Text] [Related]
18. Rationale for clinical use of immunotoxins in cancer and autoimmune disease. Byers VS; Baldwin RW Semin Cell Biol; 1991 Feb; 2(1):59-70. PubMed ID: 1954344 [TBL] [Abstract][Full Text] [Related]